Alnylam Pharmaceuticals, Inc. is seeking an Associate Director, Downstream, Emerging Modalities, to lead antibody and antibody-oligo conjugate purification strategies for early development in Cambridge, MA.
The role drives phase-appropriate process design, risk assessment, and collaboration with internal teams and external CDMOs to enable transition to human proof of concept. The candidate will author and review regulatory content, shape CMC strategies, and ensure scalable, robust purification
#J-18808-LjbffrDownstream CMC Lead for Emerging Modalities in cambridge at Unknown Company
This position is listed as full time and onsite.